nach oben

Erschienen in:

23.11.2023 | Biomarker | Zertifizierte Fortbildung Neurologie

Autoimmun-entzündliche Erkrankungen des ZNS

Biomarker zur Abschätzung der Prognose und Diagnose der Multiplen Sklerose

verfasst von: Dr. med. Catharina Korsukewitz, Univ.-Prof. Dr. med. Heinz Wiendl

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 11/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Bei der Multiplen Sklerose ist die frühe Diagnose und Prognoseabschätzung eine wichtige Voraussetzung für eine möglichst frühe und gezielte effektive Therapie. Auch wenn kein einzelner Parameter die Diagnose hinreichend gegenüber anderen Erkrankungen absichern kann, schaffen die bereits etablierten Diagnosekriterien meist eine ausreichende diagnostische Sicherheit. Dennoch besteht für die kommenden Biomarker ein großes Potenzial, den Zeitpunkt der Diagnose weiter nach vorne zu schieben und eine frühe Prognoseabschätzung zu erleichtern. …

Holstiege J et al. Trends in administrative prevalence of multiple sclerosis and utilization patterns of disease modifying drugs in Germany. Mult Scler Relat Disord. 2022;59:103534

Thompson AJ et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73

Solomon AJ et al. Differential diagnosis of suspected multiple sclerosis: an updated consensus approach. Lancet Neurol. 2023;22(8):750-68

Lebrun-Frénay Cet al. The radiologically isolated syndrome: revised diagnostic criteria. Brain. 2023;146(8):3431-43

Wiendl H et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021;14:17562864211039648

Magyari M et al. Changes in prognosis of the Danish multiple sclerosis population over time. Mult Scler. 2022;28(14):2190-201

Beiki O M et al. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden. JAMA Neurol. 2019;76(6):665-71

Landfeldt E A et al. The long-term impact of early treatment of multiple sclerosis on the risk of disability pension. J Neurol. 2018;265(3):701-7

Kopp TI T et al. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study. Mult Scler Relat Disord. 2020;40:101956

10.

Brown JWL D et al. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA. 2019;321(2):175-87

11.

He A et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307-16

12.

Iaffaldano P et al. Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Mult Scler. 2021;27(10):1543-55

13.

Hrnciarova T et al. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries. Mult Scler Relat Disord. 2023;76:104803

14.

Hartung HP et al. Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. J Neurol. 2020;267(2):308-16

15.

Okuda DT et al. Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome. Ann Neurol. 2023;93(3):604-14

16.

Van Wijmeersch B et al. Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide. Front Immunol. 2022;13:991291

17.

Khalil M et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577-89

18.

Bittner S et al. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine. 2020;56:102807

19.

Ziemssen T et al. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Front Immunol. 2022;13:852563

20.

Brune S et al. Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. Mult Scler. 2022;28(12):1859-70

21.

Kapoor R et al. Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology. 2020;95(10):436-44

22.

Buchmann A et al. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. Eur J Neurol. 2023;30(5):1389-99

23.

Barro C et al. Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;10(1):e200052

24.

Bar-Or A et al. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine. 2023;93:104662

25.

Gaetani L et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870-81

26.

Polymeris AA et al. Renal Function and Body Mass Index Contribute to Serum Neurofilament Light Chain Levels in Elderly Patients With Atrial Fibrillation. Front Neurosci. 2022;16:819010

27.

Benkert P et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022;21(3):246-57

28.

Abdelhak A et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18(3):158-72

29.

Högel H et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler. 2020;26(2):210-9

30.

Meier S et al. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurol. 2023;80(3):287-97

31.

Abdelhak A et al. Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker? Front Neurol. 2019;10:280

32.

Schindler P, Aktas O, Ringelstein M. Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review. Expert Rev Clin Immunol. 2023;19(1):71-91

33.

Vandebergh M, Dubois B, Goris A. Effects of Vitamin D and Body Mass Index on Disease Risk and Relapse Hazard in Multiple Sclerosis: A Mendelian Randomization Study. Neurol Neuroimmunol Neuroinflamm. 2022;9(3):e1165

34.

Ascherio A et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014;71(3):306-14

35.

Hupperts R et al. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a. Neurology. 2019;93(20):e1906-16

36.

Camu W et al. Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE). Neurol Neuroimmunol Neuroinflamm. 2019;6(5):e597

37.

Dobson R et al. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013;84(8):909-14

38.

Kuhle J et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler. 2015;21(8):1013-24

39.

Matute-Blanch C et al. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain. 2018;141(4):1085-93

40.

Deisenhammer F et al. The Cerebrospinal Fluid in Multiple Sclerosis. Front Immunol. 2019;10:726

41.

Hegen H et al. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis. Mult Scler. 2023;29(2):169-81

42.

Levraut M et al. Kappa Free Light Chain Index Predicts Disease Course in Clinically and Radiologically Isolated Syndromes. Neurol Neuroimmunol Neuroinflamm. 2023;10(6):e200156

43.

Pfuhl C et al. Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis. Neurology. 201;93(15):e1439-51

44.

Monreal E et al. Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome. Neurol Neuroimmunol Neuroinflamm. 202;8(5):e1047

45.

Oechtering J et al. Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. Ann Neurol. 2021;90(3):477-89

46.

Jarius S et al. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol. 2017;264(3):453-66

47.

Hottenrott T et al. The MRZ reaction helps to distinguish rheumatologic disorders with central nervous involvement from multiple sclerosis. BMC Neurol. 2018;18(1):14

48.

Vlad B et al. Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic CSF parameters and MRZ reaction. Front Neurol. 2023;14:1135392

49.

Jarius S et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2008;79(10):1134-6

50.

Alvarez E et al. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler. 2013;19(9):1204-8

51.

Schmidt C et al. A prospective study on the role of CXCL13 in Lyme neuroborreliosis. Neurology. 2011;76(12):1051-8

52.

Floro S et al. Role of Chitinase 3-like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis. Neurol Neuroimmunol Neuroinflamm. 2022;9(4):e1164

53.

Astbury L et al. CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS. J Neurol. 2023;270(4):2042-7

54.

Alvermann S et al. Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: in search of biomarkers. JAMA Neurol. 2014;71(7):905-12

55.

Gross CC et al. Classification of neurological diseases using multi-dimensional CSF analysis. Brain. 2021;144(9):2625-34

56.

Heming M et al. Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis. J Neuroimmunol. 2020;341:577171

57.

Heming M, Müller-Miny L, Rolfes L et al. Supporting the differential diagnosis of connective tissue diseases with neurological involvement by blood and cerebrospinal fluid flow cytometry. J Neuroinflammation. 2023;20(1):46

58.

Schafflick D et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat Commun. 2020;11(1):247

59.

Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019;15(5):287-300

Titel: Autoimmun-entzündliche Erkrankungen des ZNS
Biomarker zur Abschätzung der Prognose und Diagnose der Multiplen Sklerose
verfasst von: Dr. med. Catharina Korsukewitz
Univ.-Prof. Dr. med. Heinz Wiendl
Publikationsdatum: 23.11.2023
Verlag: Springer Medizin
Schlagwörter: Biomarker
Multiple Sklerose
Neurologische Diagnostik
Erschienen in: InFo Neurologie + Psychiatrie / Ausgabe 11/2023
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI: https://doi.org/10.1007/s15005-023-3454-x

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2023

Sport erhöht die Schmerztoleranz - reine Kopfsache?

Wann soll die Plättchenhemmung erneut starten?

Adäquate ADHS-Therapie hilft im Alltag

CME: EKT bei fehlender Einwilligungsfähigkeit

Genetik gibt Einblicke in die biologischen Grundlagen von Clusterkopfschmerz

Gentherapie bei Myotoner Dystrophie Typ 1